Article Text

Download PDFPDF
T090137 Inhibits Cisplatin-Induced Apoptosis in Ovarian Cancer Cells
  1. Daniel H. Miller, BS*,
  2. Andrew K. Fischer, BA*,
  3. Katrina F. Chu, BA*,
  4. Risa Burr, BS*,
  5. Sara Hillenmeyer, BA*,
  6. Laurent Brard, MD, PhD and
  7. Alexander S. Brodsky, PhD*
  1. *Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI; and
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, IL.
  1. Address correspondence and reprint requests to Alexander S. Brodsky, PhD, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, 70 Ship St, Box G, Providence, RI 02903. E-mail: Alex_brodsky{at}brown.edu.

Abstract

Objective: To determine the function of T0901317 in combination treatment with cisplatin in ovarian cancer cells.

Methods: We screened the effects of 3 nuclear hormone receptor ligands on cell viability in a panel of ovarian cancer cell lines. T0901317 regulation of apoptosis and cell cycle regulators was determined when applied as a single agent or in combination with cisplatin.

Results: Surprisingly, the liver X receptor agonist T0901317 had no significant effects on a panel of 7 ovarian cancer cell lines as a single agent. T0901317 does, however, significantly decrease cisplatin efficacy in at least 3 ovarian cancer cell lines. T0901317 reduces cisplatin-induced apoptosis and reverses cisplatin-induced expression of cell cycle regulators. T0901317 seems to work in a liver X receptor-, pregnane X receptor-, and farnesoid X receptor-independent manner, as agonists of these nuclear hormone receptors did not show similar effects. Interestingly, in the A2780-cp drug-resistant cell line, the effect of T0901317 is lost, suggesting that the pathways stimulated by T0901317 to reduce cisplatin efficacy could be inherently active features of the selected resistance.

Conclusions: Together, these data suggest that T0901317 inhibits cisplatin in some ovarian cancer cells. These data provide an avenue to investigate when T0901317 may be acting to promote tumor survival and drug resistance through control of apoptosis and when it may be acting as an antitumor agent as has been previously reported.

  • T0901317
  • LXR
  • Cisplatin
  • Ovarian cancer
  • Apoptosis

Statistics from Altmetric.com

Footnotes

  • This work was supported in part by Brown University start-up fund, a NHGRI K22 (7K22HG002488) Genome Scholar Award (A.S.B.), and NIH grant 5P41RR001395 (A.S.B).

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.ijgc.net).

  • The authors declare that there are no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.